These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14202593)

  • 21. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumor efficacy of fluoxymesterone. Use in advanced breast cancer.
    LOWE R; DE LORIMIER AA; GORDAN GS; GOLDMAN L
    Arch Intern Med; 1961 Feb; 107():241-4. PubMed ID: 13763814
    [No Abstract]   [Full Text] [Related]  

  • 23. [PRESENT STATUS OF THE TREATMENT OF CANCER OF THE BREAST].
    BORRAS JA
    Sem Med; 1963 Dec; 123():1885-91. PubMed ID: 14123099
    [No Abstract]   [Full Text] [Related]  

  • 24. Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma.
    Dilley WG; Leight GS; Silva JS; Ammirata S; Haagensen DE; Wells SA
    J Natl Cancer Inst; 1983 Jan; 70(1):69-74. PubMed ID: 6571924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal therapy in cancer of the breast. XIII. The effect of 9 alpha-fluoro-17 alpha-methyl-delta 4-androsten3-one-11 beta-17 beta-diol (fluoxymetherone) therapy on clinical course and hormonal excretion.
    SEGALOFF A; BOWERS CY; RONGONE EL; MURISON PJ; SCHLOSSER JV
    Cancer; 1958; 11(6):1187-9. PubMed ID: 13608419
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
    Skeel RT; Andersen JW; Tormey DC; Benson AB; Asbury RF; Falkson G
    Cancer; 1989 Oct; 64(7):1393-9. PubMed ID: 2505919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Long HJ; Gerstner JG; Windschitl HE
    J Clin Oncol; 1988 May; 6(5):825-31. PubMed ID: 3284975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
    Tormey DC; Lippman ME; Edwards BK; Cassidy JG
    Ann Intern Med; 1983 Feb; 98(2):139-44. PubMed ID: 6824247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROGNOSIS IN PATIENTS WITH METASTASES TO BONE FROM PRIMARY BREAST CANCER.
    ARIEL IM; LEHMAN WB
    Bull Hosp Joint Dis; 1965 Apr; 26():40-6. PubMed ID: 14333595
    [No Abstract]   [Full Text] [Related]  

  • 30. THERAPEUTIC CASTRATION IN THE TREATMENT OF ADVANCED BREAST CANCER.
    KENNEDY BJ; FORTUNY IE
    Cancer; 1964 Sep; 17():1197-202. PubMed ID: 14217765
    [No Abstract]   [Full Text] [Related]  

  • 31. THE INDICATIONS FOR 5-FLUOROURACIL IN THE TREATMENT OF BREAST CANCER.
    ANSFIELD FJ
    Geriatrics; 1965 Mar; 20():250-3. PubMed ID: 14261250
    [No Abstract]   [Full Text] [Related]  

  • 32. [The treatment of advanced breast carcinoma with fluoxymesterone. Results of 43 personal cases].
    VERONESI U; DI RE F
    Tumori; 1961; 47():453-61. PubMed ID: 13925546
    [No Abstract]   [Full Text] [Related]  

  • 33. [TREATMENT OF BREAST CANCER IN THE EARLY STAGE. APROPOS OF 407 CASES].
    ARCHAMBAULT F; HENCKES R
    Union Med Can; 1964 Sep; 93():1063-70. PubMed ID: 14183885
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical effect of fluoxymesterone in the treatment of recurrent and progressive breast neoplasms].
    Takaya O
    Horumon To Rinsho; 1977 Dec; 25(12):1371-84. PubMed ID: 598046
    [No Abstract]   [Full Text] [Related]  

  • 35. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [THERAPEUTICS OF ADVANCED CANCER OF THE BREAST].
    MARINGORRIZ FJ; SOLSONA F; CASTILLORAMIREZ A
    Clin Lab (Zaragoza); 1964 Mar; 77():175-88. PubMed ID: 14157950
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
    Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; FALKSON HC
    Cancer Chemother Rep; 1974; 58(6):939-41. PubMed ID: 4615788
    [No Abstract]   [Full Text] [Related]  

  • 39. [PREOPERATIVE ROENTGEN THERAPY OF BREAST CANCER].
    PRIEV IG
    Med Radiol (Mosk); 1963 Sep; 8():78-82. PubMed ID: 14094479
    [No Abstract]   [Full Text] [Related]  

  • 40. THYROID HORMONE AS A PROPHYLACTIC AGENT FOLLOWING RADICAL TREATMENT OF BREAST CANCER.
    LYONS AR; EDELSTYN GA
    Br J Cancer; 1965 Mar; 19(1):116-21. PubMed ID: 14284372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.